After buying a biotech startup that had developed a hepatitis drug in 2011, one big drugmaker, Gilead, charged much more for the treatment than its target had planned.

在 2011 年收购了一家开发出肝炎药物的生物技术初创公司后，一家大型制药商吉利德 (Gilead) 对治疗的收费远高于其目标计划。